PF-04928473

N/A

Report date: 2022/08/12 16:00:23

Base Information

Drug NamePF-04928473
Drug Alias NameSNX-2112PF-04928473
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeat shock protein HSP90 inhibitors
TargetsHeat shock protein HSP90
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLymphoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer IncEsanex IncSerenex Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSerenex IncPfizer IncEsanex Inc +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursHematologic NeoplasmsLymphoma +[5] 

Other Information

ATC CodeN/A
Related LinksN/A